Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female \>18 years of age at time of enrollment~* Clinical diagnosis of stable plaque type psoriasis~* Two target plaques of similar severity meeting the following criteria:~  * 5 cm2 and ≤ 100 cm2, computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter Bilaterally located (right/left) plaques on the arms or plaques located on the trunk. Plaques located on the trunk must be separated by at least 10 cm Overall target plaque severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point difference in the scores of the two target plaques~* Willing and able to apply study drug as directed, comply with study instructions and commit to all follow-up visits~* Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures~Exclusion Criteria:~* Any dermatological conditions, disease state or physical condition that could interfere with clinical evaluations or might expose the patient to an unacceptable risk by study participation~* Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below)~* Clinically significant, abnormal Screening laboratory results (unless approved by the medical monitor)~* Known sensitivity to any of the components of the study medication~* Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis~* Concomitant use of topical or systemic therapies that might alter the course of psoriasis~* Females of child bearing potential. Females must be post-menopausal (based on FSH levels) or surgically sterile (hysterectomy or bilateral oophorectomy)~* Washout periods for exclusionary therapies:~Oral retinoids: 8 weeks Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks Psoralens with UV-A (PUVA): 4 weeks Ultraviolet-B (UVB) therapy: 4 weeks Topical drugs that might alter the course of psoriasis: 2 weeks Use of emollients/moisturizers on area(s) to be treated: 2 days prior to Baseline visit~* AIDS or AIDS-related illness~* Concurrent participation in another drug or device research study or within 30 days prior to enrollment~* Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)~* Use of a beta-blocking medication (e.g., Propranolol) if the dose has not been stabilized for at least 3 months~* Use of AN2728 in a previous clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. AN2728 Ointment B (Type: ACTIVE_COMPARATOR): 2%, administered twice daily
- 2. AN2728 Ointment B Vehicle (Type: PLACEBO_COMPARATOR): None
- 3. AN2728 Ointment B (Type: ACTIVE_COMPARATOR): 2%, administered once daily
- 4. AN2728 Ointment B (Type: ACTIVE_COMPARATOR): 0.5%, administered twice daily
- 5. AN2728 Ointment B (Type: ACTIVE_COMPARATOR): 0.5%, administered once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).